Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Genelux Corp. (GNLX)
NASDAQ:GNLX
Holding GNLX?
Track your performance easily
GNLX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.60 - $16.60
Previous Close$2.49
Volume164.68K
Average Volume (3M)177.81K
Market Cap
$85.65M
Enterprise Value$53.64M
Total Cash (Recent Filing)$34.06M
Total Debt (Recent Filing)$2.04M
Price to Earnings (P/E)―
Beta-0.57
Next Earnings
Apr 07, 2025EPS Estimate
-$0.19Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.95
Shares Outstanding34,538,185
10 Day Avg. Volume222,632
30 Day Avg. Volume177,807
Standard Deviation0.47
R-Squared0.02
Alpha0.08
Financial Highlights & Ratios
Price to Book (P/B)2.59
Price to Sales (P/S)10706.84
Price to Cash Flow (P/CF)-3.70
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue6.70K
Enterprise Value/Gross Profit315.51
Enterprise Value/Ebitda-1.54
Forecast
1Y Price Target
$14.50Price Target Upside489.43% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Genelux Corp. News
PremiumCompany Announcements
Genelux Corp. Releases New Corporate Presentation
Bulls Say, Bears Say
Bulls Say
Clinical TrialsGNLX's lead program, Olvi-Vec, has the potential to selectively replicate in tumor cells, enhance neoantigen presentation, and turn 'cold' tumors 'hot.'
Innovation And Treatment PotentialOlvi-Vec has a triple mode of action, enhancing its potential effectiveness against cancer by directly killing cells, inducing an immune response, and resensitizing tumors to chemotherapy.
Strategic CollaborationsGenelux partner Newsoara, an emerging biotech company in China, is responsible for funding the Phase 2 trial of Olvi-Vec in recurrent NSCLC in the U.S.
Bears Say
Financial PerformanceGenelux reported a net loss of $6.5M, raising concerns about its financial stability despite having a cash reserve.
Market InterestDespite early enthusiasm, oncolytic viruses have historically seen limited clinical and commercial success, and as a result investor interest has waned over the years.
Therapy ConcernsThere is skepticism around the systemic dosing of oncolytic viruses due to previous therapies having safety and dilution issues, which affects expectations for positive results.
---
Ownership Overview
12.31% Insiders
3.53% Mutual Funds
5.75% Other Institutional Investors
75.25% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
GNLX FAQ
What was Genelux Corp.’s price range in the past 12 months?
Genelux Corp. lowest stock price was $1.60 and its highest was $16.60 in the past 12 months.
What is Genelux Corp.’s market cap?
Currently, no data Available
When is Genelux Corp.’s upcoming earnings report date?
Genelux Corp.’s upcoming earnings report date is Apr 07, 2025 which is in 136 days.
How were Genelux Corp.’s earnings last quarter?
Genelux Corp. released its earnings results on Nov 14, 2024. The company reported -$0.19 earnings per share for the quarter, beating the consensus estimate of -$0.196 by $0.006.
Is Genelux Corp. overvalued?
According to Wall Street analysts Genelux Corp.’s price is currently Undervalued.
Does Genelux Corp. pay dividends?
Genelux Corp. does not currently pay dividends.
What is Genelux Corp.’s EPS estimate?
Genelux Corp.’s EPS estimate is -$0.19.
How many shares outstanding does Genelux Corp. have?
Genelux Corp. has 34,538,185 shares outstanding.
What happened to Genelux Corp.’s price movement after its last earnings report?
Genelux Corp. reported an EPS of -$0.19 in its last earnings report, beating expectations of -$0.196. Following the earnings report the stock price went down -19.728%.
Which hedge fund is a major shareholder of Genelux Corp.?
Among the largest hedge funds holding Genelux Corp.’s share is Highbridge Capital Management LLC. It holds Genelux Corp.’s shares valued at N/A.
---
Genelux Corp. Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$14.50 (489.43% Upside)
$14.50 (489.43% Upside)
Blogger Sentiment
Bullish
GNLX Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 631.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.2M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-76.77%
12-Months-Change
Fundamentals
Return on Equity
-96.85%
Trailing 12-Months
Asset Growth
18.19%
Trailing 12-Months
Company Description
Genelux Corp.
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec) and others.
---
GNLX Stock 12 Month Forecast
Average Price Target
$14.50
▲(489.43% Upside)
Technical Analysis
Kala Pharmaceuticals
―
TRACON Pharmaceuticals
―
Bioxcel Therapeutics
―
Adaptimmune Therapeutics
―
Best Analysts Covering GNLX
1 Year
1 Year Success Rate
3/7 ratings generated profit
1 Year Average Return
-33.60%
reiterated a buy rating 7 days ago
Copying Jason McCarthy's trades and holding each position for 1 Year would result in 42.86% of your transactions generating a profit, with an average return of -33.60% per trade.
---